03
Nov

More than three years after inking a $750 million pact to develop Intra-Cellular’s PDE1 inhibitors for cognitive impairment caused by schizophrenia, Takeda is out.

…read more

Source: Takeda drops a $750M schizophrenia drug pact with Intra-Cellular

    

0 No comments